{
  "id": "5e319789fbd6abf43b00004a",
  "type": "factoid",
  "question": "Which molecule is inhibited by encorafenib?",
  "ideal_answer": "Encorafenib is a BRAF inhibitor. It is a promising therapy for metastatic or inoperable melanoma with a BRAF mutation.",
  "documents": [
    "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
    "http://www.ncbi.nlm.nih.gov/pubmed/27116335",
    "http://www.ncbi.nlm.nih.gov/pubmed/31114933",
    "http://www.ncbi.nlm.nih.gov/pubmed/28640105",
    "http://www.ncbi.nlm.nih.gov/pubmed/29326440",
    "http://www.ncbi.nlm.nih.gov/pubmed/30122982",
    "http://www.ncbi.nlm.nih.gov/pubmed/30018031",
    "http://www.ncbi.nlm.nih.gov/pubmed/28277830",
    "http://www.ncbi.nlm.nih.gov/pubmed/29568360",
    "http://www.ncbi.nlm.nih.gov/pubmed/29356698",
    "http://www.ncbi.nlm.nih.gov/pubmed/26673799",
    "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
    "http://www.ncbi.nlm.nih.gov/pubmed/29903896",
    "http://www.ncbi.nlm.nih.gov/pubmed/26586345",
    "http://www.ncbi.nlm.nih.gov/pubmed/29573941",
    "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
    "http://www.ncbi.nlm.nih.gov/pubmed/29210065",
    "http://www.ncbi.nlm.nih.gov/pubmed/29155017",
    "http://www.ncbi.nlm.nih.gov/pubmed/30117021"
  ],
  "snippets": [
    {
      "text": "Encorafenib (LGX818) is a promising BRAFV600E inhibitor that has efficacy against metastatic melanoma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29155017",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Using patient- and in vivo-derived melanoma cell lines with acquired BRAFi resistance, we show that combined treatment with the BRAFi encorafenib and HDACi panobinostat in 2D and 3D culture systems synergistically induced caspase-dependent apoptotic cell death.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29210065",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Importantly, combination of the BRAF inhibitors (BRAFi) vemurafenib (PLX4032), dabrafenib, or encorafenib with inhibitors dually targeting the EGFR and HER2 (such as lapatinib, canertinib, and afatinib) significantly reduced the metabolic activity and proliferative potential of CRC cells. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29326440",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "PURPOSE OF REVIEW: To describe the pharmacological properties, preclinical and clinical data of the novel V-Raf Murine Sarcoma Viral Oncogene Homolog B (BRAF)-inhibitor encorafenib (LGX818) and to compare these with established BRAF-inhibitors in the treatment of locally advanced or metastatic melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29356698",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We investigated encorafenib, a BRAF inhibitor with unique target-binding properties, alone or in combination with the MEK inhibitor binimetinib, versus vemurafenib in patients with advanced BRAFV600-mutant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29573941",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "In this study, we identify the antifolate methotrexate (MTX) as a sensitizer of acquired- and intrinsically-resistant MM cells to BRAFi's dabrafenib and encorafenib. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29568360",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We assembled a panel of melanoma cell lines with class IIa (activation segment) or IIb (p-loop) mutations and compared these with WT or V600E/K BRAF mutant cells. Cell lines and PDXs were treated with BRAFi (vemurafenib, dabrafenib, encorafenib, and LY3009120), MEKi (cobimetinib, trametinib, and binimetinib), or the combination. We identified 2 patients with BRAF L597S metastatic melanoma who were treated with dMAPKi.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29903896",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "The FDA approved the BRAF/MEK inhibitor combination encorafenib/binimetinib for patients with metastatic or inoperable melanoma with a BRAF V600E or V600K mutation.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30018031",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib (Braftovi\u2122), a BRAF inhibitor, and binimetinib (Mektovi\u00ae), a MEK inhibitor, are two orally bioavailable drugs developed by Array BioPharma. ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30117021",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib in combination with binimetinib for unresectable or metastatic melanoma with BRAF mutations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Encorafenib plus binimetinib seems likely to emerge as a valuable therapeutic alternative to established BRAF/MEK inhibitor combinations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib plus binimetinib versus vemurafenib or encorafenib in patients with BRAF-mutant melanoma (COLUMBUS): a multicentre, open-label, randomised phase 3 trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29573941",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Encorafenib plus binimetinib could represent a new treatment option for patients with BRAF-mutant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29573941",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert Opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22 months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6 months in the phase III COLUMBUS trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib (LGX818) is a promising BRAF __sup__ V600E __end_sup__  inhibitor that has efficacy against metastatic melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29155017",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Purpose:  Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Development of encorafenib for BRAF-mutated advanced melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/29356698",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Encorafenib and binimetinib for the treatment of BRAF V600E/K-mutated melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Encorafenib (LGX-818, Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib ( LGX-818 , Braftovi ) and binimetinib ( MEK-162 , Mektovi ) are small-molecule inhibitors of BRAF and MEK , respectively . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "With advances in RAF inhibitors and second-generation inhibitors including encorafenib and vemurafenib , which have been approved for treating BRAF-V600E malignancies , the combinatorial therapeutic strategies of RAF inhibitors elicit remarkable responses in patients with BRAF-V600E mCRC . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30122982",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib , with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of these inhibitors , encorafenib and binimetinib are the newest combination , which received approval by the Food and Drug Administration ( FDA ) for the treatment of BRAF V600E/K-mutated melanoma in June 2018 . ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib, a new-generation BRAF inhibitor, has been approved by FDA for the treatment of melanoma in combination with binimetinib.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31114933",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib (LGX-818, Braftovi) and binimetinib (MEK-162, Mektovi) are small-molecule inhibitors of BRAF and MEK, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Of these inhibitors, encorafenib and binimetinib are the newest combination, which received approval by the Food and Drug Administration (FDA) for the treatment of BRAF V600E/K-mutated melanoma in June 2018.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This review will focus on the preclinical pharmacology, pharmacokinetics and clinical utility of encorafenib and binimetinib in BRAF V600-mutated melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/31050693",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Encorafenib (LGX818), a potent BRAF inhibitor, induces senescence accompanied by autophagy in BRAFV600E melanoma cells.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586345",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Encorafenib (LGX818) is a new-generation BRAF inhibitor that is under evaluation in clinical trials.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26586345",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Expert opinion: While other BRAF/MEK inhibitor combinations have achieved a median overall survival (OS) of 22\u00a0months, patients with advanced BRAF mutation-positive melanoma treated with encorafenib plus binimetinib achieved a median OS of 33.6\u00a0months in the phase III COLUMBUS trial.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: Encorafenib in combination with bimetinib offers a new approach that may offer benefits over existing BRAF/MEK inhibitor combinations.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We report three male patients with metastatic BRAFV600E-mutated melanoma who developed pyogenic granulomas 16, 10, and 12 weeks after treatment initiation with the selective BRAF inhibitors vemurafenib or encorafenib (LGX818).",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/27116335",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Treatment started in November 2015, with Encorafenib and Binimetinib, new BRAF and MEK inhibitors, respectively.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28640105",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Second-line efficacy of the pan-PI3K inhibitor BKM120 with either BRAF (encorafenib)/MEK (binimetinib) inhibitor combination or the ERK inhibitor VX-11e was confirmed in vivo Amplification of MET was observed in 3 PDX models, a higher frequency than expected and a possible novel mechanism of resistance.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/26673799",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Areas covered: A brief review of current BRAF, NRAS, and C-KIT inhibitors provides background for a thorough review of newly developed agents namely binimetinib, a MEK inhibitor, encorafenib a BRAF inhibitor, and masitinib which inhibits C-KIT.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28277830",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Results: Preclinical data demonstrated that encorafenib inhibited BRAF V600E kinase activity with a prolonged off-rate and suppressed proliferation and tumor growth of BRAF V600E-mutant melanoma models.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "This improved efficacy may be related to the distinct pharmacokinetics of encorafenib, with prolonged binding to the target molecule providing greater BRAF inhibition and increased potency compared with other drugs in the same class.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/30652516",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "Phase I Dose-Escalation and -Expansion Study of the BRAF Inhibitor Encorafenib (LGX818) in Metastatic ",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
      "beginSection": "title",
      "endSection": "title"
    },
    {
      "text": "Purpose: Encorafenib, a selective BRAF inhibitor (BRAFi), has a pharmacologic profile that is distinct from that of other clinically active BRAFis.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
      "beginSection": "abstract",
      "endSection": "abstract"
    },
    {
      "text": "We evaluated encorafenib in a phase I study in patients with BRAFi treatment-na\u00efve and pretreated BRAF-mutant melanoma.",
      "document": "http://www.ncbi.nlm.nih.gov/pubmed/28611198",
      "beginSection": "abstract",
      "endSection": "abstract"
    }
  ],
  "concepts": [],
  "exact_answer": "BRAF"
}